

DAFTAR PUSTAKA

- Al-Bachaji, I.N., Al-Buhadiliy, A.K., Al-kuraishy, H.M., Al-Gareeb, A.I., 2019. Proton pump inhibitors regulate metabolic profile and glycaemic indices in patients with type 2 diabetes mellitus: A rising dawn of a new therapeutic concept. *J Pak Med Assoc* 69.
- Bahar, M.A., Setiawan, D., Hak, E., Wilffert, B., 2017. Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. *Pharmacogenomics* 18, 701–739. <https://doi.org/10.2217/pgs-2017-0194>
- Ben Ghezala, I., Luu, M., Bardou, M., 2022. An update on drug–drug interactions associated with proton pump inhibitors. *Expert Opin. Drug Metab. Toxicol.* 18, 337–346. <https://doi.org/10.1080/17425255.2022.2098107>
- Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E.B., Brancati, F.L., 2007. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. *Ann. Intern. Med.* 147, 386. <https://doi.org/10.7326/0003-4819-147-6-200709180-00178>
- Bonnet, F., Scheen, A., 2017. Understanding and overcoming metformin gastrointestinal intolerance. *Diabetes Obes. Metab.* 19, 473–481. <https://doi.org/10.1111/dom.12854>
- Chappell, L., Brown, S.A., Wensel, T.M., 2020. Evaluation of Vitamin B12 Monitoring in Patients on Concomitant Metformin and Proton Pump Inhibitors. *Innov. Pharm.* 11, 5. <https://doi.org/10.24926/iip.v11i4.3355>
- Chen, C.B., Lin, M., Eurich, D.T., Johnson, J.A., 2016. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study. *Clin. Ther.* 38, 1392–1400. <https://doi.org/10.1016/j.clinthera.2016.03.024>
- Chen, Y., Li, S., Brown, C., Cheatham, S., Castro, R.A., Leabman, M.K., Urban, T.J., Chen, L., Yee, S.W., Choi, J.H., Huang, Y., Brett, C.M., Burchard, E.G., Giacomini, K.M., 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. *Pharmacogenet. Genomics* 19, 497–504. <https://doi.org/10.1097/FPC.0b013e32832cc7e9>



2020. 2019 ESC Guidelines on diabetes, pre-diabetes, and diseases developed in collaboration with the EASD: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *Rev. Esp. Cardiol. Engl. Ed.* 73, 404. <https://doi.org/10.1016/j.rec.2020.04.007>

- Crouch, M.A., Mefford, I.N., Wade, E.U., 2012. Proton Pump Inhibitor Therapy Associated with Lower Glycosylated Hemoglobin Levels in Type 2 Diabetes. *J. Am. Board Fam. Med.* 25, 50–54. <https://doi.org/10.3122/jabfm.2012.01.100161>
- Damião, C.P., Rodrigues, A.O., Pinheiro, M.F.M.C., Cruz Filho, R.A.D., Cardoso, G.P., Taboada, G.F., Lima, G.A.B., 2016. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. *Sao Paulo Med. J.* 134, 473–479. <https://doi.org/10.1590/1516-3180.2015.01382111>
- Ding, Y., Jia, Y., Song, Y., Lu, C., Li, Y., Chen, M., Wang, M., Wen, A., 2013. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. *Eur J Clin Pharmacol.*
- Ferguson, D.D., DeVault, K.R., 2007. Medical management of gastroesophageal reflux disease. *Expert Opin. Pharmacother.* 8.
- Florez, H., Luo, Jiacong, Castillo-Florez, Sumaya, Mitsi, Georgia, Hanna, John, Tamariz, Leonardo, Palacio, Ana, Nagendran, Sukumar, and Hagan, M., 2010. Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes. *Postgrad. Med.* 122, 112–120. <https://doi.org/10.3810/pgm.2010.03.2128>
- Flory, J., Lipska, K., 2019. Metformin in 2019. *JAMA* 321, 1926. <https://doi.org/10.1001/jama.2019.3805>
- Gong, L., Goswami, S., Giacomini, K.M., Altman, R.B., Klein, T.E., 2012. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet. Genomics* 22, 820–827. <https://doi.org/10.1097/FPC.0b013e3283559b22>
- Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J., Furlong, T.J., Greenfield, J.R., Greenup, L.C., Kirkpatrick, C.M., Ray, J.E., Timmins, P., Williams, K.M., 2011. Clinical Pharmacokinetics of Metformin. *Clin. Pharmacokinet.* 50, 81–98. <https://doi.org/10.2165/11534750-000000000-00000>
- Gyawali, C.P., Fass, R., 2018. Management of Gastroesophageal Reflux Disease. *Gastroenterology* 154, 302–318. <https://doi.org/10.1053/j.gastro.2017.07.049>



Pottegård, A., Björnsson, E.S., Lund, S.H., Ogmundsdottir, rímsson, E., Ogmundsdottir, H.M., Zoega, H., 2018. Proton-ers among adults: a nationwide drug-utilization study. *Ther. Adv. l.* 11, 1756284818777943. <https://doi.org/10.1177/1756284818777943>

- Han, N., Oh, M., Park, S.M., Kim, Y.J., Lee, E.J., Kim, T.K., Kim, T.N., Kwon, M.J., Kim, M., Lee, S.H., Rhee, B.D., Park, J.H., 2015. The Effect of Proton Pump Inhibitors on Glycated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus. *Can. J. Diabetes* 39, 24–28. <https://doi.org/10.1016/j.jcjd.2013.10.008>
- Hansen, C.S., Jensen, J.S., Ridderstråle, M., Vistisen, D., Jørgensen, M.E., Fleischer, J., 2017. Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. *J. Diabetes Complications* 31, 202–208. <https://doi.org/10.1016/j.jdiacomp.2016.08.025>
- Holt, R.I.G., Flyvbjerg, A. (Eds.), 2024. Front Matter, in: *Textbook of Diabetes*. Wiley. <https://doi.org/10.1002/9781119697473.fmatter>
- Inci, F., Atmaca, M., Ozturk, M., Yildiz, S., Koceroglu, R., Sekeroglu, R., Ipekci, S.H., Kebapcilar, L., 2014. Pantoprazole may improve beta cell function and diabetes mellitus. *J. Endocrinol. Invest.* 37, 449–454. <https://doi.org/10.1007/s40618-013-0040-y>
- Jansman, F.G.A., Reyners, A.K.L., Van Roon, E.N., Smorenburg, C.H., Helgason, H.H., Le Comte, M., Wensveen, B.M., Van Den Tweel, A.M.A., De Blois, M., Kwee, W., Kerremans, A.L., Brouwers, J.R.B.J., 2011. Consensus-Based Evaluation of Clinical Significance and Management of Anticancer Drug Interactions. *Clin. Ther.* 33, 305–314. <https://doi.org/10.1016/j.clinthera.2011.01.022>
- Kim, A., Chung, I., Yoon, S.H., Yu, K.-S., Lim, K.S., Cho, J.-Y., Lee, H., Jang, I.-J., Chung, J.Y., 2014a. Effects of Proton Pump Inhibitors on Metformin Pharmacokinetics and Pharmacodynamics. *Drug Metab. Dispos.* 42, 1174–1179. <https://doi.org/10.1124/dmd.113.055616>
- Kim, A., Chung, I., Yoon, S.H., Yu, K.-S., Lim, K.S., Cho, J.-Y., Lee, H., Jang, I.-J., Chung, J.Y., 2014b. Effects of Proton Pump Inhibitors on Metformin Pharmacokinetics and Pharmacodynamics. *Drug Metab. Dispos.* 42, 1174–1179. <https://doi.org/10.1124/dmd.113.055616>
- Liu, G., Wen, J., Guo, D., Wang, Z., Hu, X., Tang, J., Liu, Z., Zhou, H., Zhang, W., 2016. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. *J. Pharmacol. Sci.* 132, 244–248. <https://doi.org/10.1016/j.jphs.2016.04.016>



y, C.J., Pearson, E.R., 2016. Metformin and the gastrointestinal
logia 59, 426–435. <https://doi.org/10.1007/s00125-015-3844-9>

U., Resch, C., Schaeffeler, E., Rius, M., Schwab, M., 2011.
p Inhibitors Inhibit Metformin Uptake by Organic Cation
(OCTs). *PLoS ONE* 6, e22163.
<https://doi.org/10.1371/journal.pone.0022163>

Nies, A.T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., Zanger, U.M., Keppler, D., Schwab, M., Schaeffeler, E., 2009. Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver†. *Hepatology* 50.

Rajput, M.A., Ali, F., Zehra, T., Zafar, S., Kumar, G., 2020. The effect of proton pump inhibitors on glycaemic control in diabetic patients. *J. Taibah Univ. Med. Sci.* 15, 218–223. <https://doi.org/10.1016/j.jtumed.2020.03.003>

Rena, G., Pearson, E.R., Sakamoto, K., 2012. Molecular action and pharmacogenetics of metformin: current understanding of an old drug. *Diabetes Manag.* 2, 439–452. <https://doi.org/10.2217/dmt.12.42>

Sattayalertyanyong, O., Thitilertdecha, P., Auesomwang, C., 2020. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. *Int. J. Clin. Pharm.* 42, 174–183. <https://doi.org/10.1007/s11096-019-00955-8>

Schoenfeld, A.J., Grady, D., 2016. Adverse Effects Associated With Proton Pump Inhibitors. *JAMA Intern. Med.* 176, 172–174. <https://doi.org/10.1001/jamainternmed.2015.7927>

Shanika, L.G.T., Reynolds, A., Pattison, S., Braund, R., 2023. Proton pump inhibitor use: systematic review of global trends and practices. *Eur. J. Clin. Pharmacol.* 79, 1159–1172. <https://doi.org/10.1007/s00228-023-03534-z>

Sim, J., Wright, C.C., 2005. The kappa statistic in reliability studies: Use, interpretation, and sample size requirements. *Phys. Ther.* 85, 257–268. <https://doi.org/10.1093/ptj/85.3.257>

Thirumurugu, S., Parthasarathy, V., Arumainayagam, D., Balasubramaniyan, S., 2010. *Research Journal of Pharmaceutical, Biological and Chemical Sciences.*

Tinajero, M.G., Malik, V.S., 2021. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. *Pandemic Diabetes Prediabetes Prev. Control* 50, 337–355. <https://doi.org/10.1016/j.ecl.2021.05.013>

Tzvetkov, M.V., Vormfelde, S.V., Balen, D., Meineke, I., Schmidt, T., Sehr, D., Sabolić, I., Koepsell, H., Brockmüller, J., 2009. The Effects of Genetic ns in the Organic Cation Transporters OCT1, OCT2, and OCT3 Clearance of Metformin. *Clin. Pharmacol. Ther.* 86, 299–306. <https://doi.org/10.1038/clpt.2009.92>



a, D., Valera, R., Plitt, A.E., Lutgen, S., 2021. Adverse Effects with Proton Pump Inhibitor Use. *Cureus.* <https://doi.org/10.7759/cureus.12759>